Modular Medical shares surge 12.36% intraday after validating Pivot controller line for Q1 2026 launch.

Modular Medical surged 12.37% intraday after announcing the successful validation of its Pivot controller manufacturing line, a critical step toward its Q1 2026 launch of a tubeless, 3-milliliter patch pump targeting the $3 billion "almost-pumper" diabetes market. The validation confirms high-volume production readiness, addressing unmet demand for affordable, user-friendly insulin delivery systems. CEO Jeb Besser emphasized the milestone as evidence of scalable manufacturing, a key differentiator in the competitive patch pump space. While the product remains pending FDA clearance, the news reduced commercialization risks and highlighted the company’s potential to capture market share through cost-effective, accessible technology. The announcement aligns with the stock’s upward trajectory, reflecting investor optimism about Modular Medical’s ability to execute its commercial strategy.